<DOC>
	<DOCNO>NCT02955459</DOCNO>
	<brief_summary>This 2-part , first-in-human dose-ranging study evaluate safety , tolerability pharmacokinetics escalate dos VNRX-5133 administer via intravenous ( IV ) infusion healthy subject . In part 1 , subject receive single dose VNRX-5133 ; part 2 subject receive VNRX-5133 7 day .</brief_summary>
	<brief_title>VNRX-5133 SAD/MAD Safety PK Healthy Adult Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Bacterial Infections</mesh_term>
	<criteria>Healthy adult Males nonpregnant , nonlactating female Body Mass Index ( BMI ) 18.5 32.0 , inclusive . Suitable vein cannulation Employee site sponsor Any disease pose unacceptable risk participant Abnormal ECG Abnormal labs Abnormal vital sign Current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , autoimmune , hematologic , neoplastic , neurological disorder Positive serology hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) type 1 Current smoker history smoking within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>